Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Shrinkage of the cerebellum (cerebellar atrophy), Low muscle tone (hypotonia), Ataxia, and Motor delay and others; and very common findings: Motor axonal neuropathy. 29 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 10 | Inability to walk, Dystonia, Global brain atrophy |
AGTPBP1 encodes ATP/GTP binding carboxypeptidase 1 (1,226 aa). Metallocarboxypeptidase that mediates protein deglutamylation of tubulin and non-tubulin target proteins. Highest expression in Brain Spinal cord cervical c-1 (35.0 TPM) and Whole Blood (33.6 TPM).
Neurodegeneration, childhood-onset, with cerebellar atrophy is caused by mutations in the AGTPBP1 gene on chromosome 9.
AGTPBP1 is classified as a druggable target (Druggable Genome and Protease categories) with score 0.0.
Genetic testing for AGTPBP1 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 6 always present features, 1 very common feature, 13 common features.
No clinical trials have been registered for neurodegeneration, childhood-onset, with cerebellar atrophy.
12 publications have been identified in PubMed for neurodegeneration, childhood-onset, with cerebellar atrophy. Research spans Basic Science / Preclinical (58%), Case Report / Case Series (25%), and Epidemiology / Natural History (8%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 7 | 58% |
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 4:30 AM UTC
Online Mendelian Inheritance in Man
Muscles |
8 |
Shrinkage of the cerebellum (cerebellar atrophy), Low muscle tone (hypotonia), Global brain atrophy |
Eyes | 3 | Strabismus, Nystagmus, Slow saccadic eye movements |
Growth and development | 1 | Failure to thrive |
Bones and joints | 1 | Skeletal muscle atrophy |
Head and neck | 1 | Microcephaly |
Digestive system | 1 | Feeding difficulties |
Lungs and breathing | 1 | Difficulty breathing due to muscle weakness (respiratory insufficiency due to muscle weakness) |
Patient case studies |
3 |
25% |
Disease patterns and progression | 1 | 8% |
New treatment approaches | 1 | 8% |
Yi S (2026). [PMID: 41534641](https://pubmed.ncbi.nlm.nih.gov/41534641/). *Clin Chim Acta*. [Case Report / Case Series]
Pan C (2026). [PMID: 40349688](https://pubmed.ncbi.nlm.nih.gov/40349688/). *Cells Tissues Organs*. [Basic Science / Preclinical]
Sartorelli J (2026). [PMID: 41833177](https://pubmed.ncbi.nlm.nih.gov/41833177/). *Mol Genet Metab*. [Epidemiology / Natural History]
Hernández-Pérez C (2026). [PMID: 41683572](https://pubmed.ncbi.nlm.nih.gov/41683572/). *Int J Mol Sci*. [Basic Science / Preclinical]
Wang HP (2025). [PMID: 40347376](https://pubmed.ncbi.nlm.nih.gov/40347376/). *Mol Neurobiol*. [Basic Science / Preclinical]
Hernández-Pérez C (2025). [PMID: 41226418](https://pubmed.ncbi.nlm.nih.gov/41226418/). *Int J Mol Sci*. [Basic Science / Preclinical]
Pérez-Revuelta L (2025). [PMID: 39859255](https://pubmed.ncbi.nlm.nih.gov/39859255/). *Int J Mol Sci*. [Basic Science / Preclinical]
Chen Q (2025). [PMID: 41317319](https://pubmed.ncbi.nlm.nih.gov/41317319/). *Cell Rep*. [Basic Science / Preclinical]
Raúl HC (2025). [PMID: 40696808](https://pubmed.ncbi.nlm.nih.gov/40696808/). *Am J Med Genet A*. [Case Report / Case Series]
Wada H (2025). [PMID: 40754822](https://pubmed.ncbi.nlm.nih.gov/40754822/). *Mol Ther*. [Gene Therapy / Novel Therapeutics]